Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer--results of a first-in-man dose-escalation study with a fixed-dose extension phase. - Isambert, N.; Delord, J.-P.; Soria, J.-C.; Hollebecque, A.; Gomez-Roca, C.; Purcea, D.; Rouits, E.; Belli, R.; Fumoleau, P. (Annals of Oncology, 2015)